VC Sofinnova appoints new parter
This article was originally published in Scrip
Sofinnova Partners, a Paris-based life science venture capital firm, has named Henrijette Richter a partner. Ms Richter joins Sofinnova from Novo Seeds, part of Novo A/S, which she co-established. She has also invested in and serves on the boards of several biotech companies such as Affinicon, Orphazyme, EpiTherapeutics, Avilex Pharma, and Lysogene.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.